| ￥3500 | |
| Z05604-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 49.9 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 67-72 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of LILRB5/CD85c/LIR-8, His & Avi，Human is greater than 95% as determined by SEC-HPLC. »
LILRB5/CD85c/LIR-8, His & Avi，Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | LILRB5, also known as CD85c andLIR-8, belongs to a family of transmembrane glycoproteins that negatively regulate immune cell activation. Mature human LIR-8 consists of a 435 amino acid (aa) extracellular domain with four Ig-like domains, a 21 aa transmembrane segment, and a 111 aa cytoplasmic domain with two immunoreceptor tyrosine-based inhibitory motifs (ITIM). LILRB5 may act as receptor for class I MHC antigens. |
| Synonyms | CD85C ; LIR-8; LIR8 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
